The $4 million investment by the Bill & Melinda Gates Foundation in Affinivax Inc.'s vaccine technology "provides us the opportunity and the runway to build out this platform and get additional points of validation, which will allow us to bring on potentially new funders, but also pharma partners," said CEO Steven Brugger. Read More
HONG KONG – After years of waiting, Chinese biosimilar makers will soon have a comprehensive set of guidelines to follow, likely tipping the scales to make the massive country one of the top markets for biosimilars. Read More
HONG KONG – Samsung Bioepis Co. Ltd., the biopharmaceutical arm of the South Korean conglomerate, is looking to take high-quality biosimilars global in just two years. For the company, which is expanding its footprint in that competitive space, it all comes down to 2016. Read More
It's a fair bet that vertebrates have been breaking bones ever since they evolved them. And for most of history, they have been on their own to fix those breaks. Evolutionarily speaking, "the orthopedic surgeon is a very recent invention," the Weizmann Institute's Elazar Zelzer told BioWorld Today. But fracture healing is "a robust process." Read More
TAIPEI, Taiwan – Twi Biotechnology Inc., the drug development arm of Taipei, Taiwan-headquartered generics firm Twi Pharmaceutical Inc., recently received orphan drug designation from the FDA for the use of its AC-201 drug candidate to topically treat epidermolysis bullosa (EB). Read More
Supreme Pharmaceuticals Inc., of Vancouver, British Columbia, increased the maximum size of its previously announced nonbrokered private placement to gross proceeds of $1.5 million. Read More
Amag Pharmaceuticals Inc., of Waltham, Mass., reported record third quarter U.S. net sales of Feraheme (ferumoxytol), its iron deficiency anemia drug for patients with chronic kidney disease. Feraheme sales hit $22.5 million in the third quarter, up 20 percent compared to $19.3 million in the third quarter of 2013. Read More
strong>Baxter International Inc., of Deerfield, Ill., said its investigational 20 percent concentration subcutaneous immunoglobulin (IGSC) treatment for primary immunodeficiencies met its efficacy and tolerability endpoints in a European phase II/III study. Read More
Critical Outcome Technologies Inc., of London, Ontario, said lead oncology candidate COTI-2 successfully completed two-species repeated-dose toxicity studies in anticipation of filing an investigational new drug application with the FDA. Read More
strong>Myos Corp., of Cedar Knolls, N.J., reported new data from its trial conducted at the University of Tampa, which examined the effects of Fortetropin in conjunction with modest resistance training in average men. Read More
Chugai Pharmaceutical Co. Ltd., of Tokyo, inked a deal with Providence, R.I.-based Epivax Inc. to incorporate Epivax's ISPRI immunogenicity screening and deimmunization technology into Chugai's drug development toolbox. Read More
